Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
Pharmaceutical companies also are investing heavily in AI-driven solutions to optimize their drug development processes, particularly by leveraging AI platforms to analyze vast datasets and accelerate discovery. The FTC nevertheless has remained focused on the life sciences/medical device sector in other parts of its enforcement efforts.
Let's personalize your content